Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis.

Georges Saab, Graeme Mindel, Gregory Ewald, Anitha Vijayan

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Milrinone is a phosphodiesterase type III inhibitor with positive inotropic and vasodilatory effects. A common side effect of milrinone is hypotension from the peripheral vasodilation. Although mild elevations in serum creatinine have been described previously in the setting of milrinone-induced hypotension, acute oligoanuric renal failure requiring renal replacement therapy has not yet been described. This case report is the first to document such a result and to report the successful use of peritoneal dialysis in this setting. Previous case reports documented vasopressin as an effective alternative to catecholamines in the treatment of milrinone-induced hypotension. This report documents the use of four vasopressor agents (including vasopressin) in this patient, with only vasopressin resulting in improvement in systemic vascular resistance and blood pressure. Vasopressin may be the most effective vasopressor agent in the treatment of milrinone-induced hypotension.

Original languageEnglish
Pages (from-to)E7
JournalAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
Volume40
Issue number2
StatePublished - Aug 2002

Fingerprint

Dive into the research topics of 'Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis.'. Together they form a unique fingerprint.

Cite this